BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15090801)

  • 1. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia.
    Bourboulia D; Aldam D; Lagos D; Allen E; Williams I; Cornforth D; Copas A; Boshoff C
    AIDS; 2004 Feb; 18(3):485-93. PubMed ID: 15090801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study.
    Sullivan SG; Hirsch HH; Franceschi S; Steffen I; Amari EB; Mueller NJ; Magouras I; Biggar RJ; Rickenbach M; Clifford GM;
    AIDS; 2010 Sep; 24(14):2245-52. PubMed ID: 20543658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active antiretroviral therapy.
    Wilkinson J; Cope A; Gill J; Bourboulia D; Hayes P; Imami N; Kubo T; Marcelin A; Calvez V; Weiss R; Gazzard B; Boshoff C; Gotch F
    J Virol; 2002 Mar; 76(6):2634-40. PubMed ID: 11861829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
    Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
    J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of immune reconstitution inflammatory syndrome-associated with kaposi sarcoma in mozambique: a prospective study.
    Letang E; Almeida JM; Miró JM; Ayala E; White IE; Carrilho C; Bastos R; Nhampossa T; Menéndez C; Campbell TB; Alonso PL; Naniche D
    J Acquir Immune Defic Syndr; 2010 Apr; 53(5):589-97. PubMed ID: 19801945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma.
    Tedeschi R; Enbom M; Bidoli E; Linde A; De Paoli P; Dillner J
    J Clin Microbiol; 2001 Dec; 39(12):4269-73. PubMed ID: 11724831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.
    Min J; Katzenstein DA
    AIDS Res Hum Retroviruses; 1999 Jan; 15(1):51-5. PubMed ID: 10024052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analysis of the humoral response to Kaposi's sarcoma-associated herpesvirus after primary infection in children.
    Olp LN; Minhas V; Gondwe C; Poppe LK; Rogers AM; Kankasa C; West JT; Wood C
    J Med Virol; 2016 Nov; 88(11):1973-81. PubMed ID: 27062052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
    Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
    J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.
    Clerici M; Seminari E; Maggiolo F; Pan A; Migliorino M; Trabattoni D; Castelli F; Suter F; Fusi ML; Minoli L; Carosi G; Maserati R;
    AIDS; 2002 Sep; 16(13):1767-73. PubMed ID: 12218388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis.
    Lidenge SJ; Tso FY; Ngalamika O; Ngowi JR; Mortazavi Y; Kwon EH; Shea DM; Minhas V; Mwaiselage J; Wood C; West JT
    J Infect Dis; 2019 Apr; 219(8):1318-1328. PubMed ID: 30452681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
    Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
    AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals.
    Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI
    Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy.
    Boivin G; Gaudreau A; Routy JP
    AIDS; 2000 Sep; 14(13):1907-10. PubMed ID: 10997393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
    J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.
    Guadalupe M; Pollock BH; Westbrook S; Redding S; Bullock D; Anstead G; Agan BK; Marconi VC; Barbieri S; Sankar V; Rebeles J; Flahive Y; Schoolfield J; Wang L; Lei X; Dow D; Yeh CK; Dang H; Infante AJ; Gao SJ
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):83-90. PubMed ID: 21084997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia.
    Wendland T; Furrer H; Vernazza PL; Frutig K; Christen A; Matter L; Malinverni R; Pichler WJ
    AIDS; 1999 Oct; 13(14):1857-62. PubMed ID: 10513643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK.
    Letang E; Lewis JJ; Bower M; Mosam A; Borok M; Campbell TB; Naniche D; Newsom-Davis T; Shaik F; Fiorillo S; Miro JM; Schellenberg D; Easterbrook PJ
    AIDS; 2013 Jun; 27(10):1603-13. PubMed ID: 23462220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.